NovoCure (NVCR) Operating Leases (2019 - 2026)

NovoCure's Operating Leases history runs 8 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• In Q1 2026, Operating Leases fell 2.06% year-over-year to $39.5 million; the TTM figure through Mar 2026 stood at $39.5 million (down 2.06% YoY), while the FY2025 annual figure was $41.6 million, up 108.54% from the prior year.
• Operating Leases came in at $39.5 million for Q1 2026 at NovoCure, down from $41.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $42.9 million in Q2 2025 to a low of $13.4 million in Q2 2022.
• A 5-year average of $26.3 million and a median of $21.7 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases retreated 27.17% in 2024 and surged 108.54% in 2025, its largest moves.
• NovoCure's Operating Leases stood at $18.8 million in 2022, then soared by 46.15% to $27.4 million in 2023, then declined by 27.17% to $20.0 million in 2024, then soared by 108.54% to $41.6 million in 2025, then dropped by 5.21% to $39.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $39.5 million, $41.6 million, and $42.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison